Sequoia Financial Advisors LLC Has $1.01 Million Position in Sanofi (NASDAQ:SNY)

Sequoia Financial Advisors LLC boosted its stake in shares of Sanofi (NASDAQ:SNY) by 2.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,003 shares of the company’s stock after purchasing an additional 425 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Sanofi were worth $1,013,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in SNY. Victory Capital Management Inc. boosted its position in Sanofi by 27.6% during the third quarter. Victory Capital Management Inc. now owns 8,669 shares of the company’s stock worth $500,000 after purchasing an additional 1,876 shares during the period. Atlanta Consulting Group Advisors LLC bought a new stake in Sanofi during the third quarter worth approximately $1,111,000. Chesapeake Capital Corp IL bought a new stake in Sanofi during the third quarter worth approximately $543,000. Thrivent Financial for Lutherans boosted its position in Sanofi by 28,890.2% during the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after purchasing an additional 1,424,289 shares during the period. Finally, Prospera Financial Services Inc boosted its position in Sanofi by 5.6% during the third quarter. Prospera Financial Services Inc now owns 11,432 shares of the company’s stock worth $659,000 after purchasing an additional 604 shares during the period. Institutional investors own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SNY. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $60.00.

Sanofi Price Performance

Shares of SNY stock opened at $57.75 on Monday. The stock has a market cap of $146.56 billion, a P/E ratio of 23.19, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a one year low of $45.22 and a one year high of $60.12. The stock has a fifty day moving average price of $53.65 and a 200 day moving average price of $52.81. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.